Navigation Links
Going with the flow
Date:9/11/2012

Scientists who study tissue engineering and test new drugs often need to sort, rotate, move, and otherwise manipulate individual cells. They can do this by prodding the cells into place with a mechanical probe or coaxing them in the desired direction with acoustic waves, electric fields, or flowing fluids. Techniques that rely on direct physical contact can position individual cells with a high level of precision while non-contact techniques are often faster for sorting large numbers of cells. An international team of researchers has now developed a way to manipulate cells that combines some of the benefits of both contact and non-contact methods. The researchers suspended a tiny plate in a microfluidic channel and used magnetic controls to move the plate up and down and back and forth. The movements generated fluid flow patterns that varied depending on characteristics of the oscillations such as frequency, magnitude, and phase, and the relative position of the plate and the channel wall. Changing these parameters allowed the researchers to create different streamlines that either pulled or pushed a cell toward or away from the plate, as well as vortices that rotated the cell. When the cell reached the plate the researchers could also use the plate for precise, direct-contact manipulations. The researchers demonstrated the technique, which they describe in a paper published in the American Institute of Physics' journal Applied Physics Letters, by manipulating a single bovine egg cell. As a next step, the team plans to demonstrate control of multiple cells simultaneously.


'/>"/>

Contact: Catherine Meyers
cmeyers@aip.org
301-209-3088
American Institute of Physics
Source:Eurekalert

Page: 1

Related biology news :

1. Preventing the immune system from going haywire during sepsis
2. The physics of going viral
3. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... by eating the leaves of an invasive tree that soaks ... down water loss in the Southwestern United States. Two ... U.S. Geological Survey and the U.S. Department of Agriculture, have ... result from using Asian beetles for the biological control of ...
... WEST LAFAYETTE, Ind. - A Purdue University scientist and ... improved plant growth regulators that are expected to be ... of horticulture, said the growth inhibitors block the transport ... the plant, controls growth processes. Current growth regulators that ...
... whose work has overtones of Indiana Jones as they ... that could become the source of life-saving new medicines, ... international agreement on biodiversity will affect their work. That,s ... News (C&EN), ACS,s weekly newsmagazine. C&EN Associate ...
Cached Biology News:Scientists study control of invasive tree in western US 2Scientists study control of invasive tree in western US 3New growth inhibitors more effective in plants, less toxic to people 2
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
(Date:4/16/2015)... ROCKLAND, Mass. , April 16, 2015 /PRNewswire/ ... of Merck KGaA, Darmstadt, Germany ... Senior Vice President, Head of Global Clinical Development. ... development expertise, including experience in Oncology and Immunology. ... leadership ability, having served as a Vice President ...
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ... personalized immune therapies for cancer, announced today that ... Immunotherapy Index (LCINDX), a professional index recently established ... within the biotechnology space.  The ... in the immunotherapy space, including 6 big pharma ...
Breaking Biology Technology:Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... Biopharmaceuticals (Nasdaq: KERX ) today announced completion ... its Phase 3 registration program of Zerenex™, the Company,s ... serum phosphorus levels, or hyperphosphatemia, in patients with end-stage ... registration program, which is being conducted pursuant to a ...
... NEW HAVEN, Conn., Sept. 19, 2011 The U.S. ... of allowance related to Cenestra Health,s high-purity omega-3 fatty ... claims cover a range of high-purity omega-3 formulations including ... Cenestra Health was issued U.S. Patent No. ...
... 16, 2011 Generex Biotechnology Corporation ( www.generex.com ... Napolii, from University Campus Bio-Medico in Rome, Italy, ... on Generex Oral-lyn™ buccal insulin spray on September ... Study of Diabetes (EASD) annual meeting in Lisbon, ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 4Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 2Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 2Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 4
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... Natural and Recombinant RNasin Ribonuclease Inhibitors have ... inhibition of eukaryotic RNases of the neutral ... inhibitory effect by noncovalently binding to RNases ... for the binding of RNasin Ribonuclease Inhibitor ...
Biology Products: